Приказ основних података о документу

dc.creatorGossec, Laure
dc.creatorSmolen, Josef S.
dc.creatorRamiro, Sofia
dc.creatorWit, Maarten de
dc.creatorCutolo, Maurizio
dc.creatorDougados, Maxime
dc.creatorEmery, Paul
dc.creatorLandewe, Robert
dc.creatorOliver, Susan
dc.creatorAletaha, Daniel
dc.creatorBetteridge, Neil
dc.creatorBraun, Juergen
dc.creatorBurmester, Gerd R.
dc.creatorCanete, Juan D.
dc.creatorDamjanov, Nemanja
dc.creatorFitzGerald, Oliver
dc.creatorHaglund, Emma
dc.creatorHelliwell, P.
dc.creatorKvien, T. K.
dc.creatorLories, Rik
dc.creatorLuger, Thomas
dc.creatorMaccarone, Mara
dc.creatorMarzo-Ortega, Helena
dc.creatorMcGonagle, Dennis
dc.creatorMcInnes, Iain B.
dc.creatorOlivieri, Ignazio
dc.creatorPavelka, Karel
dc.creatorSchett, Georg
dc.creatorSieper, Joachim
dc.creatorvan den Bosch, F.
dc.creatorVeale, Douglas J.
dc.creatorWollenhaupt, Juergen
dc.creatorZink, Angela
dc.creatorvan der Heijde, D.
dc.date.accessioned2018-03-01T16:43:25Z
dc.date.available2018-03-01T16:43:25Z
dc.date.issued2016
dc.identifier.issn0003-4967
dc.identifier.issn1468-2060
dc.identifier.urihttps://vinar.vin.bg.ac.rs/handle/123456789/955
dc.description.abstractBackground Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. Methods A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. Results The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL) 12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. Conclusions These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.en
dc.relationEULAR [CLI079]
dc.rightsopenAccessen
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceAnnals of the Rheumatic Diseasesen
dc.titleEuropean League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 updateen
dc.typearticleen
dc.rights.licenseBY
dcterms.abstractМаццароне, М.; Госсец, Л.; Цутоло, М.; Лориес, Р.; Ландеwе, Р.; Павелка, К.; ФитзГералд, О.; Дамјанов, Н.; Цанете, Ј. Д.; ван дер Хеијде, Д.; Сцхетт, Г.; Браун, Ј.; Хаглунд, Е.; Беттеридге, Н.; Aлетаха, Д.; Емерy, П.; Доугадос, М.; Рамиро, С.; Лугер, Т.; ван ден Босцх, Ф.; Квиен, Т. К.; Сиепер, Ј.; МцГонагле, Д.; Оливиери, И.; МцИннес, И. Б.; Зинк, A.; Веале, Д. Ј.; Марзо-Ортега, Х.; Wолленхаупт, Ј.; Бурместер, Г.; Оливер, С.; Смолен, Ј. С.; де Wит, М.; Хеллиwелл, П.;
dc.citation.volume75
dc.citation.issue3
dc.citation.spage499
dc.citation.epage510
dc.identifier.wos000371077700004
dc.identifier.doi10.1136/annrheumdis-2015-208337
dc.citation.rankM21a
dc.identifier.pmid26644232
dc.type.versionpublishedVersion
dc.identifier.scopus2-s2.0-84960126976
dc.identifier.fulltexthttps://vinar.vin.bg.ac.rs//bitstream/id/14331/951.pdf


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу